Table 1 Anthropometric and biochemical data

From: Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers

 

Control

SS

NASH

Male / female (n)

6 / 3

13 / 6

8 / 15

Age (years)

36.4 ± 4.3

47.5 ± 3.0

55.3 ± 3.0a

Body mass index (kg/m2)

22.0 ± 1.3

27.3 ± 0.9a

27.3 ± 0.8a

Prevalence of obesity (%)

11.1

68.4

78.3

Prevalence of hypertension (%)b

0.0

25.0

39.1

HbA1c (%)c

5.3 ± 0.1

5.7 ± 0.1

5.8 ± 0.1d

HbA1c (mmol/mol)c

34.4 ± 1.3

38.6 ± 1.0

40.1 ± 1.0d

Fasting plasma glucose (mg/dL)

93.0 ± 3.4

96.9 ± 2.3

98.6 ± 2.1

Fasting serum insulin (µU/mL)e

—

13.9 ± 2.8

21.9 ± 2.3f

HOMA-IRe

—

3.5 ± 0.7

5.3 ± 0.6f

AST (IU/L)

17.6 ± 8.1

36.7 ± 5.6a

67.3 ± 4.3a

ALT (IU/L)

18.0 ± 13.0

67.8 ± 9.0a

74.8 ± 6.9a

Total cholesterol (mg/dL)

187.8 ± 10.0

210.4 ± 9.9

185.3 ± 9.0

Triglycerides (mg/dL)

104.2 ± 24.1

158.1 ± 16.6

144.5 ± 15.2

Serum type IV collagen (ng/mL)g

—

94.6 ± 17.7

162.3 ± 11.7h

Serum hyaluronic acid (ng/mL)i

—

48.0 ± 43.5

105.6 ± 25.5

  1. Data are means ± SEM or numbers (n)
  2. P was determined by ANOVA with Tukey–Kramer post hoc testing
  3. HOMA-IR homeostatic model assessment insulin resistance, AST aspartate aminotransferase, ALT alanine aminotransferase, SS simple steatosis, NASH non-alcoholic steatohepatitis
  4. aP < 0.01 vs. control
  5. bAvailable for all 9 control subjects, 12 of the 19 SS subjects and 22 of 23 NASH subjects
  6. cAvailable for 6 of the 9 control subjects, 17 of the 19 SS subjects and all 23 NASH subjects
  7. dP < 0.05 vs. Control
  8. eAvailable for 16 of the 19 SS subjects and all 23 NASH subjects
  9. fP < 0.05 vs. SS
  10. gAvailable for 8 of the 19 SS subjects and 18 of the 23 NASH subjects
  11. hP < 0.01 vs. SS
  12. iAvailable for 7 of the 19 SS subjects and 21 of the 23 NASH subjects
Back to article page